What guidance did Intellia's management provide for the next earnings period?

What is the market's earnings forecast for Intellia next quarter?

What were the key takeaways from Intellia's earnings call?

What were the key takeaways from Intellia’s earnings call?

What factors drove the changes in Intellia's revenue and profit?

What is the revenue and EPS growth rate for Intellia year over year?

What is Intellia's gross profit margin?

What does Intellia do and what are its main business segments?

- **ATTR Program Update:** FDA lifted hold on MAGNITUDE-2 with safety modifications; MAGNITUDE remains on hold. lonvo-z Phase III enrollment complete, with 76% attack-free rate in early trials.
- **Financial Strength:** $605M cash balance supports operations. lonvo-z's mid-single-digit market share could fund operations independently.
- **Safety Focus:** <1% of ATTR patients experienced severe liver enzyme elevations; steroid regimen implemented to mitigate risk.
- **Commercial Momentum:** Scaling teams for lonvo-z launch; 54% of U.S. HAE patients identified as potential candidates.

**【CEO Summary Section】**
- **ATTR Amyloidosis Program (nex-z):** Phase III trials (MAGNITUDE for cardiomyopathy, MAGNITUDE-2 for polyneuropathy) faced a clinical hold due to liver enzyme elevations. FDA lifted hold on MAGNITUDE-2 with modifications (steroid regimen for elevated LFTs, enhanced liver monitoring). Enrollment in MAGNITUDE-2 resumed, targeting 60 patients. MAGNITUDE remains on hold as FDA evaluates safety data.
- **HAE Program (lonvo-z):** Phase III HAELO trial completed enrollment of 80 patients ahead of schedule. lonvo-z achieved 76% attack-free rate in Phase I/II trials, with no waning efficacy over 3 years. Topline data expected mid-2026, with BLA submission planned for late 2026.
- **Commercial Readiness:** Scaling field medical, sales, and reimbursement teams. Distribution model and pricing strategy under development. lonvo-z's one-time treatment profile aims to reduce long-term costs for patients and payers.

**【CFO Financial Commentary】**
- **Cash Position:** $605.1M as of Q4 2025, sufficient for operations into H2 2027. Collaboration revenue increased 78% YoY to $23M (driven by Regeneron partnership). R&D expenses decreased 24% YoY to $88.7M (lower employee costs, offset by clinical trial expenses). Net loss narrowed 26% YoY to $95.8M.
- **Financial Outlook:** lonvo-z's potential mid-single-digit market share in HAE could generate sufficient cash flow to fund operations, reducing reliance on external financing.

**【Q&A Highlights】**
- **ATTR Safety Concerns:** Liver enzyme elevations (Grade 4) occurred in <1% of MAGNITUDE patients, likely immune-mediated. FDA-approved steroid use post-dosing to mitigate risk. No long-term liver damage observed in resolved cases.
- **HAE Commercial Strategy:** Targeting young, treatment-naive patients for lonvo-z. Payers recognize cost savings of one-time therapy vs. lifelong LTPs. Field medical team engaged with 4,000+ patients, 54% of U.S. HAE population.
- **Manufacturing Readiness:** lonvo-z uses commercial-scale manufacturing processes. CDMO partners validated for global distribution. No comparability testing needed between Phase III and commercial material.
- **Competitive Landscape:** Emphasized lonvo-z's durability vs. RNA-based therapies requiring repeat dosing. Patient burden of prior authorization for LTPs highlighted as key differentiator.

Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript

- **ATTR Cardiomyopathy Expansion**: 1,200-patient Phase III study targets 650+ patients by year-end, powered to show statistical significance for Nex-z + stabilizer combination.
- **Clinical Success**: LONVOZI Phase I shows 3-year attack-free period; NEX-Z reduces TTR by 90% within 1 month, with ATTR polyneuropathy patients achieving 13/18 clinically meaningful improvements.
- **Financial Strength**: $630M cash balance supports 2027+ runway, with 10% YoY expense decline and collaboration revenue up 106%.
- **Strategic Differentiation**: Gene-editing therapies offer one-time cure vs. chronic treatments, with lonvo-z eliminating HAE attacks and Nex-z addressing unmet ATTR needs.

**【CEO Summary Section】**
- **Clinical Momentum**: Phase III trials for LONVOZI (HAE) and NEX-Z (ATTR) are enrolling faster than expected, with 650+ ATTR cardiomyopathy patients targeted by year-end (up from 550). Expansion to 1,200 patients in the ATTR cardiomyopathy study aims to enhance statistical power, particularly for patients on stabilizers.
- **Operational Excellence**: HALO study (LONVOZI) completed enrollment 4 months ahead of schedule, screening 41 patients in April alone. ATTR polyneuropathy trial (NEX-Z) expects 50+ patients randomized by mid-2026.
- **Strategic Adaptation**: Study size increase reflects rapid TTR reduction (e.g., 225→17 mcg/mL in wild-type ATTR cardiomyopathy) and commercial differentiation via Nex-z + stabilizer combination.
- **Leadership Transition**: CMO David Lebwohl to retire in August 2026, with succession planning underway.

**【CMO Clinical Updates】**
- **LONVOZI (HAE)**: 3-year Phase I data shows 0 attacks post-treatment, with 23-month median attack-free period. Phase II update doubles 50mg dose patients to >30, supporting safety/tolerability.
- **NEX-Z (ATTR)**: Phase I data shows 90% TTR reduction within 1 month, with cardiomyopathy patients showing stable/improved biomarkers (e.g., proBNP, 6-minute walk). ATTR polyneuropathy patients saw 13/18 achieving clinically meaningful MNIS+7 improvement at 24 months.
- **Enrollment Dynamics**: 70%+ ATTR cardiomyopathy patients on stabilizers (tafamidis/vutrisiran), driven by standard-of-care shifts. Strong demand despite competing therapies.

**【CFO Financial Commentary】**
- **Cash Position**: $630.5M as of Q2 2025, supporting runway into H1 2027. Collaboration revenue up 106% YoY to $14.2M (Regeneron cost reimbursements).
- **Expense Management**: R&D/G&A down 17%/15% YoY, guided for ~10% YoY decline. Stock-based comp $22.1M in Q2 (R&D: $14.1M, G&A: $8M).
- **Operational Efficiency**: Restructuring benefits offset clinical trial expansion costs, maintaining guidance for 2027 cash runway.

**【Q&A Highlights】**
- **Study Expansion Feasibility**: CFO confirms cash runway unaffected by 1,200-patient expansion, citing conservative scenario planning and modest incremental costs.
- **Payer Dynamics**: CEO emphasizes one-time therapy cost-effectiveness vs. chronic treatments, with lonvo-z offering 0 attacks and no ongoing therapy.
- **Competitive Landscape**: ATTR cardiomyopathy market dominated by wild-type (90%), positioning Nex-z as unique TTR reducer with deep, rapid reductions (e.g., 132→17 mcg/mL in hereditary ATTR).
- **Blind Study Integrity**: LONVOZI Phase III maintains blinding despite high response rates, with objective attack metrics reducing bias.


Intellia Therapeutics (NTLA)-7 Aug 25-2025 Q2 Earnings call transcript

- **Landmark Clinical Progress**: Dosed first patients in both Phase 3 studies, marking 2/6 2025 milestones achieved.
- **FDA Recognition**: 3 RMAT designations for lead programs, solidifying regulatory confidence.
- **Commercial Readiness**: Expanded team and $707M cash war chest support 2027 HAE launch.
- **Enrollment Momentum**: >550 ATTR-CM patients enrolled YTD, HAELO on track for Q3 2025 completion.
- **Financial Discipline**: 5-10% OpEx decline, $95M/quarter cash burn, no dilutive financing needs until 2027.

**【CEO Summary Section】**
- Completed first patient dosing in Phase 3 studies for HAE (HAELO) and hereditary ATTR with polyneuropathy (MAGNITUDE 2), achieving 2 of 6 2025 milestones.
- Received FDA RMAT designation for nex-z in ATTR-CM, bringing total RMAT designations to 3 across lead programs.
- Expanded commercial team with expertise in one-time therapies, targeting 2027 HAE launch.

**【Clinical Updates】**
- HAELO Phase 3 enrollment progressing ahead of schedule, with >90% of patients on long-term prophylaxis, aiming for Q3 2025 completion.
- MAGNITUDE Phase 3 for ATTR-CM enrolling >550 patients YTD, with 90+ global sites active.
- NTLA-2002 Phase 1/2 data shows 90% TTR reduction at 1 month vs 9 months for competitor, with no attacks in >80% of patients.

**【Financial Highlights】**
- $707.1M cash balance as of Q1 2025, down 18% YoY due to restructuring and real estate portfolio optimization.
- GAAP R&D expenses $108.4M (-3% YoY), G&A $29M (-7% YoY), driving 5-10% OpEx decline guidance.
- $95M/quarter cash burn projected for 2025-2026, supporting Phase 3 studies and 2027 HAE launch.

**【Q&A Key Takeaways】**
- ATTR-CM enrollment unaffected by Vutrisiran approval, with >50% patients on Tafamidis and strong investigator interest.
- NTLA-2002 pricing strategy to reflect $1M+ annual cost of chronic therapies, targeting 2027 launch with >30% gross margin.
- FDA engagement stable, with no timeline impacts from regulatory changes; BLA submission for HAE expected in 2026 as planned.

Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript

- **ATTR Dominance**: Nex-z achieves 90% TTR reduction vs. 80% for competitors, with 12-month cardiac stabilization in severe cardiomyopathy patients.
- **HAE Breakthrough**: 80% attack-free rate in Phase II, with 2026 BLA targeting one-time cure for hereditary angioedema.
- **Cost Efficiency**: 5-10% OpEx decline in 2025 via restructuring, enabling 2027 commercial launch without dilutive equity raises.
- **Pipeline Focus**: Resources redirected to 3 Phase III programs (HAE, ATTR-CM, ATTR-PN), with 2027-2030 launch cadence.


**【CEO Business Highlights】**
- **HAE Pipeline Momentum**: Phase III HAELO study for NTLA-2002 targeting 60 patients, with first patient dosed in January 2025. Expected BLA filing in 2026 for one-time treatment with potential functional cure.
- **ATTR Expansion**: Phase III MAGNITUDE study for ATTR cardiomyopathy on track to exceed 550 patients by year-end 2024, with 50-patient MAGNITUDE-2 study for ATTR polyneuropathy set to dose first patient in Q1 2025.
- **Pipeline Restructuring**: Discontinued NTLA-3001 to focus resources on late-stage programs, aligning with commercial readiness for 2027 launches.

**【CFO Financial Update】**
- **Cash Position**: $861.7M as of Q4 2024, down from $1B in 2023, supporting clinical and commercial investments.
- **Revenue Growth**: Collaboration revenue up $14.8M YoY to $12.9M, driven by Regeneron partnership.
- **Cost Management**: R&D expenses +7.9% YoY to $116.9M, G&A +11.7% YoY to $32.4M. Restructuring aims for 5-10% YoY OpEx decline in 2025 via workforce reduction and program deprioritization.

**【CMO Clinical Progress】**
- **Nex-z in ATTR-CM**: Phase I data shows 90% TTR reduction at 12 months, with 17mcg/mL residual TTR. Cardiac hospitalization rate 12% vs. 25% in controls, despite severe baseline disease.
- **ATTR-PN Efficacy**: MAGNITUDE-2 study targeting 50 patients with 91% TTR reduction at 12 months, with mNIS+7 and mBMI improvements.
- **HAE Functional Cure**: Phase II crossover data shows 50mg dose achieves attack-free status in 80% of patients, with extended follow-up planned for 2025.

**【Q&A Key Takeaways】**
- **OpEx Trajectory**: 2025 GAAP OpEx decline of 5-10% via restructuring, with clinical trial costs peaking in 2025 before winding down post-2026.
- **ATTR Competition**: Nex-z TTR knockdown (17mcg/mL) superior to AMVUTTRA (55mcg/mL), positioning for differentiated efficacy in 2028 BLA.
- **Commercial Readiness**: U.S. launch infrastructure build in 2025-2026, with global partnerships under evaluation for ex-U.S. expansion.
- **HAE Reimbursement**: Single-dose outpatient regimen avoids steroid burden, aligning with patient preference for functional cure over prophylaxis.


Actual										-0.63	-0.61	-0.47	-0.69	-0.69	-1.01	-0.97	-1.09	-1.96	-1.33	-1.49	-1.4	-1.17	-1.4	-1.38	-1.46	-1.12	-1.52	-1.34	-1.27	-1.1	-0.98	-0.83
Forecast										-0.4323	-0.6911	-0.5908	-0.6025	-0.6579	-0.6342	-0.8471	-0.949	-1.109	-1.3039	-1.2854	-1.3787	-1.3995	-1.3209	-1.4985	-1.4385	-1.3662	-1.2168	-1.3901	-1.3307	-1.279	-1.0177	-0.9412
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-45.73%	+11.73%	+20.45%	-14.52%	-4.88%	-59.26%	-14.51%	-14.86%	-76.74%	-2.00%	-15.92%	-1.54%	+16.40%	-5.99%	+7.91%	-1.49%	+18.02%	-24.92%	+3.60%	+4.56%	+14.00%	+3.70%	+11.81%

NTLA

NTLA fundamentals

NTLA Q4 2025 Earnings

Earnings Call

You can ask Aime

NTLA

NTLA fundamentals

NTLA Q4 2025 Earnings

Earnings Call

NTLA Earnings Call Summary for Q4/20258:00 AM on Feb 26, 2026

NTLA Earnings Call Summary for Q2/20258:00 AM on Aug 7, 2025

NTLA Earnings Call Summary for Q1/20258:00 AM on May 8, 2025

NTLA Earnings Call Summary for Q4/20248:00 AM on Feb 27, 2025

NTLA Earnings Call Summary for Q3/20248:00 AM on Nov 7, 2024

You can ask Aime